Spots Global Cancer Trial Database for A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Official Title: A Phase II Open-label Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Study ID: NCT02057380
Conditions
Study Description
Brief Summary: The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site US10004, La Jolla, California, United States
Site US10006, Tampa, Florida, United States
Site US10002, Baltimore, Maryland, United States
Site US10008, Ann Arbor, Michigan, United States
Site US10001, Oklahoma City, Oklahoma, United States
Site BR55005, Porto Alegre, Rio Grande Do Sul, Brazil
Site CZ42001, Ostrava-Poruba, , Czechia
Site DE49002, Berlin, , Germany
Site DE49001, Wuerzburg, , Germany
Site PL48001, Szczecin, Zachodniopomorskie, Poland
Site SG65002, Singapore, , Singapore
Site TH66003, Khon Kaen, , Thailand
Contact Details
Name: Executive Medical Director
Affiliation: Astellas Pharma Global Development, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
